Company Description
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo.
The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
The company was incorporated in 1996 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Nov 29, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Raul R. Rodriguez |
Contact Details
Address: 611 Gateway Boulevard, Suite 900 South San Francisco, California 94080 United States | |
| Phone | 650-624-1100 |
| Website | rigel.com |
Stock Details
| Ticker Symbol | RIGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001034842 |
| CUSIP Number | 766559603 |
| ISIN Number | US7665596034 |
| Employer ID | 94-3248524 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raul R. Rodriguez | President, Chief Executive Officer and Director |
| Dean L. Schorno CPA | Executive Vice President and Chief Financial Officer |
| Raymond J. Furey J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| David A. Santos | Executive Vice President and Chief Commercial Officer |
| Julie Patel | Senior Vice President of Human Resources |
| Dr. Esteban S. Masuda | Executive Vice President of Research |
| Joseph Lasaga | Executive Vice President and Chief Business Officer |
| Dr. Lisa Rojkjaer M.D. | Executive Vice President and Chief Medical Officer |
| Tarek Sallam | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |